Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone acts as a synthetic progestogen with anti‑mineralocorticoid and anti‑androgen properties, while ethinylestradiol is a synthetic estrogen. Together they bind to progesterone and estrogen receptors, inhibiting the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), which prevents ovulation. They also thicken cervical mucus and modify the endometrium, reducing the chance of implantation.

The dosing regimen for Mywy is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a 21‑day active tablet sequence followed by a hormone‑free interval, but the exact schedule, tablet strength and duration must be confirmed by the prescriber based on individual patient needs and local guidelines.

Mywy is contraindicated during pregnancy; it must be discontinued if pregnancy is confirmed. The product is also not recommended for breastfeeding women because hormonal contraceptives can affect milk production and infant exposure. Women should discuss alternative contraception options with their healthcare provider if they are pregnant or nursing.

To place an order, submit an enquiry on the Mywy product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details—including any special handling—and assists with the necessary import documentation.

Mywy contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgen effects, potentially providing benefits such as reduced water retention and improvement in acne compared with formulations that contain other progestins. Efficacy in preventing pregnancy is comparable to other combined oral contraceptives when taken correctly. Choice of product often depends on individual risk factors, side‑effect profile and clinician preference.

Mywy tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use tablets that are past the expiration date. No special refrigeration is required, but avoid storing in humid or excessively hot environments to maintain product stability.

Mywy is taken orally, usually once each day at the same time, with or without food. The typical regimen involves a series of active tablets followed by a hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the prescribing information and start a new pack after the interval to maintain continuous contraceptive coverage. Missed tablets should be taken as soon as remembered, and additional contraceptive measures may be needed.

The most serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, and severe allergic reactions. Women with a history of clotting disorders, smoking over age 35, uncontrolled hypertension, or certain liver diseases are at higher risk. Prompt medical attention is required if symptoms such as leg pain, shortness of breath, chest pain, severe headache, or signs of an allergic reaction develop while using Mywy.

Mywy is contraindicated for women who are pregnant or suspect pregnancy, have known or suspected estrogen‑dependent tumors, active or history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients. It should also be avoided by women over 35 who smoke heavily. Healthcare providers must assess individual medical history before prescribing Mywy to ensure safety.